1. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma Clark, Joseph I.; Singh, Jatinder; Ernstoff, Marc S.; Lao, Christopher D.; Flaherty, Lawrence E.; Logan, Theodore F.; Curti, Brendan; Agarwala, Sanjiv S.; Taback, Bret; Cranmer, Lee; Lutzky, Jose; Luna, Theresa L.; Aung, Sandra; Lawson, David H. 2018 Articles Cancer--ImmunotherapyInterleukin-2Melanoma--TreatmentEnzyme inhibitors
2. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden Morrison, Carl; Pabla, Sarabjot; Conroy, Jeffrey M.; Nesline, Mary K.; Glenn, Sean T.; Dressman, Devin; Papanicolau-Sengos, Antonios; Burgher, Blake; Andreas, Jonathan; Giamo, Vincent; Qin, Moachun; Wang, Yirong; Lenzo, Felicia L.; Omilian, Angela; Bshara, Wiam; Zibelman, Matthew; Ghatalia, Pooja; Dragnev, Konstantin; Shirai, Keisuke; Madden, Katherine G.; Tafe, Laura J.; Shah, Neel; Kasuganti, Deepa; de la Cruz-Merino, Luis; Araujo, Isabel; Saenger, Yvonne M.; Bogardus, Margaret; Villalona-Calero, Miguel; Diaz, Zuanel; Day, Roger; Eisenberg, Marcia; Anderson, Steven M.; Puzanov, Igor; Galluzzi, Lorenzo; Gardner, Mark; Ernstoff, Marc S. 2018 Articles Melanoma--TreatmentCancer--ImmunotherapyBiochemical markersMedicine